Geron 8-K 2008
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On May 14, 2008, Geron Corporation (the “Company”) publicly disseminated a press release announcing that the Company had received verbal notice today from the U.S. Food and Drug Administration (FDA) that the Company’s Investigational New Drug (IND) submission for GRNOPC1, the Company’s human embryonic stem cell-derived therapy for spinal cord injury, has been placed on clinical hold.
The foregoing description is qualified in its entirety by reference to the Company’s Press Release dated May 14, 2008, a copy of which is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.